Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 12/20 | 0.57 |
| ▸ | F10 | P00742 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TNKS | O95271 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5737920 | 0.90 | PTGS2 (0.55) | PTGS2F10MEN1KMT2ATNKS | |
| SCHEMBL1627878 | 0.84 | HPGD (0.54) | PTGS2F10MEN1NPC1RAB9A | |
| SCHEMBL76558 | 0.83 | F10 (0.58) | PTGS2F10TNKS | |
| SCHEMBL18630668 | 0.81 | F10 (0.54) | PTGS2F10 | |
| SCHEMBL2540317 | 0.81 | F10 (0.54) | PTGS2F10 | |
| SCHEMBL19751 | 0.81 | F10 (0.50) | PTGS2F10 | |
| SCHEMBL19456 | 0.81 | PTGS2 (0.64) | PTGS2F10MEN1KMT2A | |
| SCHEMBL15846877 | 0.81 | F10 (0.54) | PTGS2F10 | |
| SCHEMBL92872 | 0.81 | PTGS2 (0.64) | PTGS2F10 | |
| SCHEMBL15628319 | 0.81 | F10 (0.54) | PTGS2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118530233-A | Preparation method of rivaroxaban and intermediate thereof | 武汉工程大学 | 2024-08-23 | — | — | CN | claimed |
| CN-104788444-B | The preparation method of razaxaban | 浙江天顺生物科技有限公司 | 2018-11-06 | — | — | CN | claimed |
| CN-104860936-B | A kind of preparation method of razaxaban | 浙江天顺生物科技有限公司 | 2018-05-22 | — | — | CN | claimed |
| CN-103804221-B | A kind of Preparation Method And Their Intermediate of 4-(4-aminophenyl)-3-morpholone | 湖北迅达药业股份有限公司 | 2016-09-14 | — | — | CN | claimed |
| CN-104860936-A | Rivaroxaban preparation method | ZHEJIANG TIANSHUN BIOTECHNOLOGY CO LTD | 2015-08-26 | — | — | CN | claimed |
| CN-104829551-A | Method for preparing rivaroxaban midbody 4-(4-aminophenyl)-3-morpholone | ZHEJIANG TIANSHUN BIOTECHNOLOGY CO LTD | 2015-08-12 | — | — | CN | claimed |
| CN-104788444-A | Preparation method of rivaroxaban | ZHEJIANG TIANSHUN BIOTECHNOLOGY CO LTD | 2015-07-22 | — | — | CN | claimed |
| EP-1664004-B1 | METHOD FOR THE PRODUCTION OF 4-(4-AMINOPHENYL)-3-MORPHOLINON | BAYER IP GMBH (DE) | 2015-06-24 | — | — | EP | claimed |
| CN-103804221-A | Preparation method of 4-(4-amino phenyl)-3-morpholone and intermediate of 4-(4-amino phenyl)-3-morpholone | HUBEI XUNDA PHARMACEUTICAL CO LTD | 2014-05-21 | — | — | CN | claimed |
| JP-4852419-B2 | — | — | 2012-01-11 | — | — | JP | claimed |
| US-7598378-B2 | Method for the production of 4-(4-aminophenyl)-3-morpholinone | BAYER SCHERING PHARMA AG (DE) | 2009-10-06 | — | — | US | claimed |
| CN-100430384-C | Method for the production of 4-(4-aminophenyl)-3-morpholinon | BAYER HEALTHCARE AG (DE) | 2008-11-05 | — | — | CN | claimed |
| US-20070066611-A1 | Method for the production of 4-(4-aminophenyl)-3-morpholinone | BAYER HEALTHCARE AG (DE) | 2007-03-22 | — | — | US | claimed |
| CN-1852902-A | Process for preparing 4- (4-aminophenyl) -3-morpholinone | BAYER HEALTHCARE AG (DE) | 2006-10-25 | — | — | CN | claimed |
| EP-1664004-A1 | METHOD FOR THE PRODUCTION OF 4-(4-AMINOPHENYL)-3-MORPHOLINON | Bayer HealthCare AG (DE) | 2006-06-07 | — | — | EP | claimed |
| WO-2005026135-A1 | METHOD FOR THE PRODUCTION OF 4-(4-AMINOPHENYL)-3-MORPHOLINON | BAYER HEALTHCARE AG (DE) | 2005-03-24 | — | — | WO | claimed |
| CN-1049431-C | Morpholine and thiomorpholine tachykinin receptor antagonists | MERCK & CO INC (US) | 2000-02-16 | — | — | CN | claimed |
| CN-118530233-A | Preparation method of rivaroxaban and intermediate thereof | 武汉工程大学 | 2024-08-23 | — | — | CN | disclosed |
| EP-1317013-A1 | NON-AQUEOUS ELECTROLYTE AND SECONDARY CELL USING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2003-06-04 | — | — | EP | disclosed |
| EP-0748320-A1 | PRODRUGS OF MORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 1996-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066611-A1 | Method for the production of 4-(4-aminophenyl)-3-morpholinone | ADH5, ADH1C, ADH1A | PTGS2 1411/4885F10 1398/4885MEN1 1182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.